Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus

Background Neuropsychiatric systemic lupus erythematosus (NPSLE) is a poorly understood and heterogeneous manifestation of SLE. Common major NPSLE syndromes include strokes, seizures, myelitis, and aseptic meningitis. Easily obtainable biomarkers are needed to assist in early diagnosis and improve o...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2024-09, Vol.33 (10), p.1116-1129
Main Authors: Kammeyer, Ryan, Chapman, Kimberly, Furniss, Anna, Hsieh, Elena, Fuhlbrigge, Robert, Ogbu, Ekemini A., Boackle, Susan, Zell, JoAnn, Nair, Kavita V., Borko, Tyler L., Cooper, Jennifer C., Bennett, Jeffrey L., Piquet, Amanda L.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aseptic meningitis
Autonomic nervous system
Biomarkers
Biomarkers - blood
Blood levels
Case-Control Studies
Central nervous system diseases
Child
Demyelinating diseases
Demyelination
Disease
Female
Glial fibrillary acidic protein
Glial Fibrillary Acidic Protein - blood
Humans
Immunotherapy
Lupus
Lupus Vasculitis, Central Nervous System - blood
Male
Meningitis
Mental disorders
Middle Aged
Myelitis
Neurofilament Proteins - blood
Neuroglia - metabolism
Neuroglia - pathology
Neurological complications
Neuronal-glial interactions
Neurons - pathology
Neuropathy
Polyneuropathy
Seizures
Sensorimotor system
Spinal cord
Systemic lupus erythematosus
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Neuropsychiatric systemic lupus erythematosus (NPSLE) is a poorly understood and heterogeneous manifestation of SLE. Common major NPSLE syndromes include strokes, seizures, myelitis, and aseptic meningitis. Easily obtainable biomarkers are needed to assist in early diagnosis and improve outcomes for NPSLE. A frequent end-result of major syndromes is neuronal or glial injury. Blood-based neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) have been utilized as markers for monitoring disease activity and/or severity in other neurodegenerative and neuroinflammatory diseases; however, they have not been evaluated in active major NPSLE. Methods This was a case-control study. We enrolled patients aged 12-60 years with active major NPSLE, SLE without active major NPSLE, and healthy controls. Active NPSLE was defined as being
ISSN:0961-2033
1477-0962
1477-0962
DOI:10.1177/09612033241272961